Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AlgiSys Biosciences is a biotechnology company focused on the sustainable production of high-quality Omega-3 fatty acids, specifically EPA and DHA, through a proprietary microalgae fermentation process. The company's technology provides a vegan, non-GMO, and contaminant-free alternative to fish oil, addressing the growing global demand for heart, brain, and joint health supplements. AlgiSys targets multiple markets including human nutraceuticals, pharmaceuticals, infant formula, and animal health. By utilizing a scalable heterotrophic fermentation platform, the company ensures a consistent and traceable supply of essential fatty acids without depleting marine resources. Their process is designed to be cost-competitive with traditional fish oil while offering superior purity and sustainability.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AlgiSys Biosciences.